Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SCH 66712

Known as: SCH66712 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Metabolic phenotype can be affected by multiple factors, including allelic variation and interactions with inhibitors. Human… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
2015
2015
Cytochrome P450 enzymes (CYPs) are a heme-containing enzyme superfamily that have a major role in the metabolism of drugs in… Expand
2015
2015
Cytochrome P450s (CYPs) are heme-containing enzymes that metabolize small organic molecules including drugs. CYP3A4 and CYP2D6… Expand
2014
2014
Cytochrome P450 enzymes (CYPs) represent an important enzyme superfamily involved in metabolism of many endogenous and exogenous… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Human cytochrome P450 3A4 (CYP3A4) is responsible for the metabolism of more than half of pharmaceutic drugs, and inactivation of… Expand
2012
2012
Human cytochrome P450 2D6 (CYP2D6) is involved in metabolism of approximately 25% of pharmaceutical drugs. Inactivation of CYP2D6… Expand
2011
2011
5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine (SCH 66712) is a potent mechanism-based inactivator of… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 6
  • figure 4
2001
2001
SCH 66712 [5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine] caused a time- and NADPH-dependent loss of… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • table 1
1999
1999
SCH 66712 is a potent and selective dopamine D4 receptor antagonist. An HPLC method was developed for the analysis of SCH 66712… Expand